Levofloxacin Plus Metronidazole SuppositoriesLevofloxacin co-administered with Metronidazole tablets
Levofloxacin Plus Metronidazole Suppositories: Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
Levofloxacin co-administered with Metronidazole tablets: Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
Study summary
This is a single randomised controlled trial. The investigators plan to randomise 800 participants to the levofloxacin plus metronidazole suppositories versus levofloxacin co-administered with metronidazole tablets for the treatment of chronic endometritis in a 1:1 rate. Primary outcome will be the live birth rate after the embryo transfer.
Eligibility
Sex
FEMALE
Min age
20 Years
Max age
42 Years
Healthy volunteers
No
Inclusion Criteria:
* Infertile patients aged 20-42 years
* Hysteroscopy and endometrial biopsy were performed, and the
* Pathological diagnosis was chronic endometritis
* Serum FSH level on the second day of menstruation was ≤12U/L
* Agree and sign the informed consent form
Exclusion Criteria:
* Patients with the following diagnoses: submucosal myoma; Uterine malformation or previous surgery for correction of uterine deformity; Intrauterine adhesions; The previous history of pelvic tuberculosis or endometrial tuberculosis or the current pathology suggested endometrial tuberculosis; Endometrial hyperplasia or endometrial cancer
* Patients with spouse, previous fetal or child chromosomal abnormalities who plan to undergo preimplantation genetic screening
* Patients with a history of allergy to study drugs
Primary outcome measure(s)
live birth rate after the first embryo transfer — 22 weeks to 43 weeks gestation after the first embryo transfer cycle Live birth is defined as the delivery of at least one baby after 22 weeks of gestation Oversight that exhibits any sign of life.
Trial sites (1)
Facility
City
Region
Status
Peking university third hospital
Beijing
China
More Peking University Third Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.